SLFN11 and small cell lung carcinoma: In the majority of SCLC with low SLFN11 expression, resistance to PARP inhibition may be overcome by pharmacologic ATR inhibition [37], further supporting the role for DDR synthetic lethality in enhancing response to PARP inhibitors in SCLC.